Repository logo
 

Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy.


Change log

Authors

Guariso, Graziella 
Pozza, Laura Visona' Dalla 
Ross, Alexander 
Heuschkel, Robert 

Abstract

BACKGROUND: Most children with Inflammatory Bowel Disease (IBD) are diagnosed between 11 and 16 years of age, commonly presenting with features of typical IBD. Children with onset of gut inflammation under 5 years of age often have a different underlying pathophysiology, one that is genetically and phenotypically distinct from other children with IBD. We therefore set out to assess whether children diagnosed after the age of 5 years, but before the age of 11, have a different clinical presentation and outcome when compared to those presenting later. METHODS: Retrospective cohort study conducted at two European Paediatric Gastroenterology Units. Two cohorts of children with IBD (total number = 160) were compared: 80 children diagnosed between 5 and 10 years (Group A), versus 80 children diagnosed between 11 and 16 (Group B). Statistical analysis included multiple logistic regression. RESULTS: Group A presented with a greater disease activity (p = 0.05 for Crohn's disease (CD), p = 0.03 for Ulcerative Colitis (UC); Odds Ratio 1.09, 95 % Confidence Interval: 1.02-1.1), and disease extent (L2 location more frequent amongst Group A children with CD (p = 0.05)). No significant differences were observed between age groups in terms of gastro-intestinal and extra-intestinal signs and symptoms at disease presentation, nor was there a difference in the number of hospitalisations due to relapsing IBD during follow-up. However, children in Group A were treated earlier with immunosuppressants and had more frequent endoscopic assessments. CONCLUSION: While clinicians feel children between 5 and 10 years of age have a more severe disease course than adolescents, our analysis also suggests a greater disease burden in this age group. Nevertheless, randomized trials to document longer-term clinical outcomes are urgently needed, in order to address the question whether a younger age at disease onset should prompt per se a more "aggressive" treatment. We speculate that non-clinical factors (e.g. genetics, epigenetics) may have more potential to predict longer term outcome than simple clinical measures such as age at diagnosis.

Description

Keywords

Age, Children, Inflammatory Bowel Disease (IBD), Location, Outcomes, Presentation, Severity, Adalimumab, Adolescent, Adrenal Cortex Hormones, Age of Onset, Anti-Bacterial Agents, Anti-Inflammatory Agents, Case-Control Studies, Child, Child, Preschool, Cohort Studies, Colitis, Ulcerative, Crohn Disease, Digestive System Surgical Procedures, Disease Progression, Female, Hematocrit, Hemoglobins, Hospitalization, Humans, Inflammatory Bowel Diseases, Infliximab, Italy, Leukocyte Count, Logistic Models, Male, Mesalamine, Platelet Count, Retrospective Studies, Severity of Illness Index, Tertiary Care Centers, United Kingdom

Journal Title

BMC Gastroenterol

Conference Name

Journal ISSN

1471-230X
1471-230X

Volume Title

Publisher

Springer Science and Business Media LLC